← All countries · Europe
84%
MCV1
2025 · WHO/UNICEF estimate
97%
DTP3
2025 · WHO/UNICEF estimate
97%
IPV complete
2025 · WHO/UNICEF estimate
97%
HepB3
2025 · WHO/UNICEF estimate
40
Measles cases
2025 reported
3,693
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2009 · WHO/UNICEF estimate | 98% | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 94.7% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 97%2025 · WHO/UNICEF estimate | 96.9% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 97%2025 · WHO/UNICEF estimate | 94.7% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 97%2025 · WHO/UNICEF estimate | 96.9% | C · weak | |
| MCV1First dose of measles-containing vaccine | 84%2025 · WHO/UNICEF estimate | 83.7% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 84%2025 · WHO/UNICEF estimate | — | A · strong | |
| RCV1First dose of rubella-containing vaccine | 84%2025 · WHO/UNICEF estimate | 83.7% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 97%2025 · WHO/UNICEF estimate | 96.9% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 100%2017 · Administrative (country-reported) | 100% | D · poor | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 97%2025 · WHO/UNICEF estimate | 96.9% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | —% · Administrative (country-reported) | — | too few points | no data |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | —% · Administrative (country-reported) | — | too few points | no data |
| RotaCRotavirus vaccine, complete series | —% · Administrative (country-reported) | — | too few points | no data |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 70%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 70%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 50%2025 · WHO/UNICEF estimate | — | C · weak |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 402025 | 3.8per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 682025 | 6.4per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 3,6932025 | 348.1per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 102025 | 0.9per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | B · good | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 392025 | 3.7per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 72025 | 0.7per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (31 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | M1 | Risk group(s) | Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation) |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions | |
| DTAPDTaP (acellular) vaccine | 4 | Y5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBHEPBIPVDTaP-Hib-HepB-IPV (acellular) vaccine | 3 | M11 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | Risk group(s) | Administrated to newborns of HBsAg positive mothers |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y11-Y14 | HPV administered to females and males | 2 and 4 valent vaccine administered; females and males |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M5-M13 | HPV administered to females and males | 2 and 4 valent vaccine administered; females and males |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y11-Y14 | HPV administered to females and males | 2 and 4 valent vaccine administered; females and males |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M6 | HPV administered to females and males | 2 and 4 valent vaccine administered; females and males |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 65+ |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M13 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y5 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | >=Y65 | Adults | Older adults |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | RSV vaccination during pregnancy for all women who have not been vaccinated against RSV infection in the past and who are due to give birth in the months of October to March. For children born in the months of April to September, we prefer immunization with nirsevimab before the upcoming RSV season. The monoclonal antibody nirsevimab is administered to newborns or infants only once before or during the RSV season and is indicated for all children whose mothers were not vaccinated during pregnancy. The monoclonal antibody palivizumab is approved to prevent RSV infection for children with risk factors. | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Y50-Y64 | Risk group(s) | 50-64 years with risk factors: chronic lung and respiratory diseases, heart, kidney, liver, neurological, hematological and metabolic diseases |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | General/routine | RSV vaccination during pregnancy for all women who have not been vaccinated against RSV infection in the past and who are due to give birth in the months of October to March. For children born in the months of April to September, we prefer immunization with nirsevimab before the upcoming RSV season. The monoclonal antibody nirsevimab is administered to newborns or infants only once before or during the RSV season and is indicated for all children whose mothers were not vaccinated during pregnancy. The monoclonal antibody palivizumab is approved to prevent RSV infection for children with risk factors. | |
| RSV_MONORSV (Respiratory syncytial virus) monoclonal antibodies | 1 | Risk group(s) | RSV vaccination during pregnancy for all women who have not been vaccinated against RSV infection in the past and who are due to give birth in the months of October to March. For children born in the months of April to September, we prefer immunization with nirsevimab before the upcoming RSV season. The monoclonal antibody nirsevimab is administered to newborns or infants only once before or during the RSV season and is indicated for all children whose mothers were not vaccinated during pregnancy. The monoclonal antibody palivizumab is approved to prevent RSV infection for children with risk factors. | |
| TDAP_S_IPVTdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine | 5 | Y10 | General/routine | |
| TTTT (Tetanus toxoid) vaccine | 1 | Adults | Regular booster vaccination every 10-15 years in adult population | |
| TTTT (Tetanus toxoid) vaccine | 6 | Y25 | Adults | Regular booster vaccination every 10-15 years in adult population, therefore 6th dose is in Y25 |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.